Latest Us Market News

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Cochlear Limited has secured FDA approval for its latest Nucleus Nexa System and Kanso 3 sound processors, setting the stage for a US market debut in early FY26.

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

Anson Resources has expanded its Green River Lithium Project in Utah by acquiring 100 new placer claims, increasing the landholding by 10% and identifying promising re-entry targets in historical wells to potentially enhance lithium resource estimates.

Cobram Estate Olives has reported a record 2025 Australian olive harvest with a 10.2% increase in production and forecasts a strong FY2025 EBITDA of $115 million. The company also announces strategic moves including a CEO relocation to the US and acquisition of farming machinery business Leda Ag.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Aumake Limited unveils a major FY26 restructuring, splitting operations into two focused units and targeting acquisitions in health supplements to boost profitability and market reach.

Tourism Holdings Limited trims its FY25 profit guidance to the lower end of analyst expectations, citing ongoing challenges in global RV sales and a potential goodwill impairment tied to its US operations.

Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

The Calmer Co. International Limited has reported a striking 86% revenue jump to over AU$8 million in FY25, propelled by diversified sales channels and a strategic US expansion highlighted by new flavoured kava shots launched exclusively on Amazon USA.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.